

Image 1645

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450

Alexandria, VA 22313 on February 24, 2004

Frank C. Eisenschenk

Frank C. Eisenschenk, Ph.D., Patent Attorney

THIRD SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Examining Group 1645

Patent Application

Docket No. G-101US05REG

Serial No. 10/051,681

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Kenneth R. Horlick
Art Unit : 1645
Applicants : Daniel Cohen, Ilya Chumakov
Serial No. : 10/051,681
Filed : January 16, 2002
Conf. No. : 1458
For : Treatment of CNS Disorders Using D-Amino Acid Oxidase and D-Aspartate Oxidase Antagonists

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332


Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: 2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

FCE/mdp

Attachments: Form PTO/SB/08; copies of references cited therein.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/051,681
Filing Date	January 16, 2002
First Named Inventor	Daniel Cohen
Group Art Unit	1645
Examiner Name	Kenneth R. Horlick
Attorney Docket Number	G-101US05REG

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	LEESON, P. <i>et al.</i> "The Glycine Site on the NMDA Receptor: Structure-Activity Relationships and Therapeutic Potential", November 25, 1994, pp. 4053-4067, Vol. 37, No. 24.	
	R2	WOOD, P. "Current Status of NMDA-Associated Glycine Site Modulators in the Treatment of Alzheimer's Disease", 1997, pp. 245-251, Vol. 2, No. 5.	
	R3		
	R4		
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.